“This case challenges current paradigms, demonstrating that amivantamab monotherapy can effectively target rare EGFR mutations, achieve durable extracranial and CNS disease control, and potentially ...

This new article publication from Acta Pharmaceutica Sinica B, discusses key challenges in targeted treatment of brain metastatic non-small cell lung cancer. Over the past two decades, marked progress ...

An interdisciplinary multi-center research team led by the LKS Faculty of Medicine (HKUMed) and Faculty of Dentistry at the University of Hong Kong has constructed the world's largest multi-omics ...

Brain metastases are a common problem in patients with EGFR-mutated non-small cell lung cancer (NSCLC), occurring in about one-fifth to one-quarter of patients. Many brain metastases will be ...

A single-arm phase 2 trial showed that patritumab deruxtecan (HER3-DXd) demonstrated meaningful clinical activity in pretreated patients with metastatic breast cancer and active brain metastases, ...

Panelists discuss how the 5-year CROWN trial data for lorlatinib have shaped the treatment paradigm for ALK+ metastatic non-small cell lung cancer (NSCLC), particularly regarding long-term survival, ...

Using single-cell transcriptomics to reveal CD226 upregulation and enhancement of CD19-CAR-T function in the inhibitory CNS microenvironment of refractory CNS lymphoma. A phase I/II study to assess ...

Efficacy and Safety of Denileukin Diftitox-Cxdl, an Improved Purity Formulation of Denileukin Diftitox, in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma Patients (N = 119) with ≥one ...

Brain metastases often occur as a result of advanced cancer and, despite medical innovations, are still associated with a poor prognosis. Now, an international expert committee has taken an important ...